弥漫性大B细胞淋巴瘤中DNA损伤反应通路与BCL-2的双重靶向
研究在DLBCL中探讨MYC/BCL-2阳性及双打击淋巴瘤对化疗耐药的生物学基础,整合靶向基因表达谱、FISH和氧化应激标志物分析两个独立队列,发现氧化DNA损伤标志物可识别预后不良的双表达亚群。体外和体内双打击DLBCL模型证实DNA损伤反应联合BCL-2抑制具有协同疗效。
要点
- 氧化DNA损伤标志物可识别预后不良的双表达DLBCL亚群
- 该亚群BCL-2表达较高且富集双打击淋巴瘤
- DNA损伤反应联合BCL-2抑制在双打击模型中显示协同疗效
核心结论
- DNA损伤反应激活和BCL-2过表达可能是MYC/BCL-2阳性淋巴瘤预后差和化疗耐药的生物学基础。
- 联合抑制DNA损伤反应和BCL-2在双打击DLBCL模型中显示协同疗效,为精准治疗提供依据。
研究设计与样本
- 研究整合靶向基因表达谱、荧光原位杂交分析和复制及氧化应激标志物表征,在两个独立DLBCL队列中进行。
- 基于发现,在体外和体内双打击DLBCL模型中测试DNA损伤反应联合BCL-2抑制的治疗策略。
主要发现
- 氧化DNA损伤标志物的存在识别出预后不良的双表达DLBCL亚群。
- 该亚群具有相对较高的BCL-2基因表达水平并富集双打击淋巴瘤。
- 联合DNA损伤反应和BCL-2抑制在体外和体内双打击DLBCL模型中确认疗效和协同相互作用。
临床怎么用
- 氧化DNA损伤标志物可能用于识别预后不良的双表达DLBCL患者。
- DNA损伤反应联合BCL-2抑制策略可能适用于双打击或双表达DLBCL的精准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient's population characterized by refractoriness to anthracycline-based chemotherapy. Here we hypothesized that adaptive mechanisms to MYC-induced replicative and oxidative stress, consisting in DNA damage response (DDR) activation and BCL-2 overexpression, could represent the biologic basis of the poor prognosis and chemoresistance observed in MYC/BCL-2-positive lymphoma. We first integrated targeted gene expression profiling (T-GEP), fluorescence in situ hybridization (FISH) analysis, and characterization of replicative and oxidative stress biomarkers in two independent DLBCL cohorts. The presence of oxidative DNA damage biomarkers identified a poor prognosis double expresser (DE)-DLBCL subset, characterized by relatively higher BCL-2 gene expression levels and enrichment for DH lymphomas. Based on these findings, we tested therapeutic strategies based on combined DDR and BCL-2 inhibition, confirming efficacy and synergistic interactions in in vitro and in vivo DH-DLBCL models. These data provide the rationale for precision-therapy strategies based on combined DDR and BCL-2 inhibition in DH or DE-DLBCL.
引用
- Rossi A, Orecchioni S, Falvo P, et al. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. Leukemia. 2021. PMID: 34304248. doi:10.1038/s41375-021-01347-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。